Posted by Michael Wonder on 12 Jul 2023
Better Therapeutics receives FDA authorisation for AspyreRx to treat adults with type 2 diabetes
10 July 2023 - In a randomised controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c.
Better Therapeutics today announced that the FDA authorised AspyreRx (formerly BT-001), a prescription only digital therapeutic treatment indicated to provide cognitive behavioural therapy to patients 18 years or older with type 2 diabetes.
